Nucor earnings beat by $0.08, revenue fell short of estimates
Mark E. Dmytruk, the Chief Financial Officer of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA), recently executed a transaction involving the company’s stock. On March 4, 2025, Dmytruk sold 790 shares of Ginkgo Bioworks’ Class A Common Stock at a price of $7.725 per share, totaling approximately $6,102. The transaction occurs as the stock trades near $7.81, having gained 46% over the past six months despite a year-to-date decline of 16%. According to InvestingPro analysis, the company appears undervalued based on its Fair Value estimate.
The sale was conducted to cover tax withholding obligations related to the vesting of restricted stock units, as per the company’s equity incentive plans. These transactions are not discretionary trades by the reporting person. Following this transaction, Dmytruk holds 34,652 shares directly. The company maintains strong liquidity with a current ratio of 5.62 and holds more cash than debt on its balance sheet. Discover more insights about DNA’s financial health and 12 additional ProTips with InvestingPro.
In other recent news, Ginkgo Bioworks reported a 29% increase in cell engineering revenue for the fourth quarter of 2024, reaching $35 million. The company’s full-year cell engineering revenue totaled $174 million, while adjusted EBITDA for the quarter improved significantly, reducing losses from $101 million in Q4 2023 to $57 million. Despite these positive financial metrics, Ginkgo Bioworks experienced a 15.16% drop in stock price following the earnings call, indicating investor caution. The company also provided revenue guidance for 2025, estimating a range of $160 to $180 million, with cell engineering revenue expected between $110 and $130 million. Ginkgo Bioworks aims to achieve adjusted EBITDA breakeven by the end of 2026. Additionally, the company highlighted new product launches and AI-driven data services as potential growth drivers. Ginkgo Bioworks maintains a strong cash position, ending the quarter with $562 million, and continues to focus on cost reductions and operational efficiency. Analyst firms noted these developments, suggesting a cautious yet optimistic outlook for the company’s future growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.